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The Year in Valvular Heart Disease
Shahbudin H. Rahimtoola, MB, FRCP, DSC (HON)
Los Angeles, CaliforniaGuidelines on Valvular Heart Disease
A. European Society of Cardiology and the European
Association for Cardio-Thoracic Surgery (1). Comment:
A total of 46 pages and 241 references. Of the 66 recom-
mendations, none had Level of Evidence: A. There were 28
Class I recommendations with Level of Evidence: B in 6 and
C in 22. There were 31 Class IIa recommendations with
Level of Evidence: B in 1 and C in 30. There are 7 Class IIb
recommendations; all were with Level of Evidence: C.Aortic Stenosis
A. Mechanisms. 1. North Western Adelaide Health
Study. This study evaluated changes over a time period of 4
years in 204 randomly selected subjects age 63 6 years who
had aortic sclerosis (ASc) (2). The authors demonstrated: 1)
progression occurs in the majority of the normal aging
population; 2) the importance of the nitric oxide signaling
cascade in disease development; and 3) provided additional
data linking angiotensin-converting enzyme inhibitor/
angiotensin II receptors with the retardation of ASc.
2. Study of aortic stenosis (AS)/ASc and aortic
atherosclerosis. Position emission and computed tomog-
raphy was performed using 18F-sodium ﬂuoride and 18F-
ﬂuorodeoxyglucose (18F-FDG) in 101 patients with calciﬁc
aortic valve disease from Scotland (3). The results showed
that AS/ASc are distinctly different processes from aortic
atherosclerosis and skeletal bone formation. In AS/ASc,
active calciﬁcation was more pronounced and inﬂammation
was less prominent than in aortic atherosclerosis. In AS,
endothelial nitric oxide synthase uncoupling is markedly
increased, and the pathophysiological processes are locally
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2013, accepted January 7, 2014.Comment: This study complements an earlier study (4).
The accompanying editorial points out that both calciﬁc
aortic valve disease and aortic atherosclerosis are very com-
mon in the older population and that a correlation does not
necessarily imply a cause-and-effect relationship (5).
3.Genetics associationswithvalvular calciﬁcationsandAS.
One single-nucleotide polymorphism (SNP) in the lipo-
protein (a) [Lp(a)] locus (LPA, rs10455872) reached
genome-wide signiﬁcance for the presence of aortic valve
calciﬁcation (odds ratio [OR] per allele 2.05, p ¼ 9.0 
1010). This ﬁnding was replicated in additional white Eu-
ropean, African-American, andHispanic-American cohorts
(6). Genetically determined Lp(a) levels, as predicted by
LPA genotype, were also associated with aortic valve calci-
ﬁcation, “supporting a causal role for Lp(a).” The authors
concluded: “We have identiﬁed a SNP in the LPA locus that
is signiﬁcantly correlated with aortic-valve calciﬁcation. Our
ﬁndings implicate genetic variation at the LPA locus,
through elevated plasma Lp(a) levels, in the development of
aortic-valve disease.”
Comment: The accompanying editorial by Dorn (7) is
excellent. It emphasizes that the frequency of the LPA gene
variant is 0.03. Thus, 5 or 6 persons in 100 carry this risk
allele, whereas calciﬁcation of the aortic valve occurs
commonly.
4. Role of osteogenic progenitor cells in calciﬁc AS.
Blood from patients with mild-to-moderate AS (n ¼ 17),
severe calciﬁc AS (n ¼ 26), severe AS/severe coronary artery
disease (CAD) (n ¼ 33), and controls (n ¼ 22) were
examined (8). Patients with severe AS showed a higher
number of endothelial progenitor cells (EPC) with osteo-
blastic phenotype (OCN) than did controls. Immunoﬂuo-
rescence showed colocalization of nuclear factor kappa-B
and OCN in diseased and normal valves. CD34þ/OCNþ
cells were abundant in the endothelial and deeper layers of
calciﬁc AS. The authors concluded EPC-OCN may play a
signiﬁcant role in the pathogenesis and as markers of
prognostication of calciﬁc AS.
B. Assessment of severe AS. 1. Criteria for severe AS:
mean aortic valve gradient (AVG) is problematic; aortic
valve area (AVA) £1.0 cm2 is reliable. In an “elderly”
community, in Olmsted County, Minnesota, which repre-
sents the “community practice” of the Mayo Clinic “whose
personnel perform all cardiology services.” There were
360 residents who had AS diagnosed by echocardiography
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1949from 1988 to 1997 (9); 96 of them had severe AS
(AVA <1.0 cm2), but 67% had a mean aortic valve gradient
(AVG) of <40 mm Hg, and in 32%, the mean AVG
was <30 mm Hg and left ventricular ejection fraction
(LVEF) was 0.50. The reasons for not performing aortic
valve replacement (AVR) included low gradient in 57%,
symptoms judged equivocal in 43%, comorbidities 37%,
patient refusal of surgery in 20%, and physician choice in
20%. In patients who did not have surgery, the survival was
worse for those with AVA <1.0 cm2 (Fig. 1). AVR was
ultimately performed in 131 patients, who comprised only
45% of those with AVA <1.0 cm2, which reduced mortality
(hazard ratio [HR]: 0.61, 95% conﬁdence interval [CI]:
0.39 to 0.94, p ¼ 0.02) and heart failure (HR: 0.29, 95% CI:
0.13 to 0.64, p < 0.01).
Comment: There are 3 problems: 1) In this age group,
a large majority of patients with severe AS (AVA
index 0.6 cm2/m2) had a mean AVG <40 mm Hg (10) as
in this study. One criteria of severe AS that is used is mean
AVG >40 mm Hg, which is being interpreted to indicate
that a mean AVG 40 mm Hg is not severe AS, as was
also common in this study (9). It is best if the criteria of
>40 mm Hg is discarded. Alternatively, it needs to be
emphasized that mean AVG >40 mm Hg may indicate
severe AS, but its speciﬁcity and positive predictive value are
not known. However, in a study of 636 patients, mean AVG
50 mm Hg was documented to be speciﬁc, and the pos-
itive predictive value for severe AS was 90% (11). More-
over, it is best to rely on calculated AVA; 2) symptoms were
not attributed to AS; and 3) physician choice.
C. Prognosis of severe AS. 1. Aortic valve area index
(AVAI) by echocardiographic/Doppler is a predictor of
event-free survival. In 103 consecutive asymptomaticFigure 1 Survival of Elderly Patients With AS in a Community
Survival during management of patients with aortic stenosis (AS) without aortic
valve replacement according to baseline aortic valve area (AVA). The numbers
along each curve indicate the survival at 5 and 8 years. Patients with mild AS
(orange) and moderate AS (green) have similar survival. There is a higher mor-
tality in those with severe AS (blue) and AVA <1.0 cm2. Reprinted with permission
from Malouf et al. (9).patients, age 72  11 years, those with AVAI of <0.6 cm2/
m2 versus those with AVAI 0.6 cm2/m2 had 3-year event-
free survival of 41% versus 86%, respectively, p < 0.01 (12).
Actuarial total mortality data were not presented.
2. Energy loss index (ELI) is also a predictor of event-
free survival but is controversial for total mortality. Data
from the SEAS (Simvastatin and Ezetimibe in Aortic Ste-
nosis) study of 1,563 patients with AS who were initially
asymptomatic showed that ELI <0.6 cm2/m2 “provided
additional prognostic information to that derived from
conventional measures of AS severity” (13). In patients with
ELI <0.6 cm2/m2, the incidence of aortic valve events was 3
times greater over 5 to 6 years than in those with larger ELI.
Overall survival was said to also be better; however, their
Figure 1B shows that at 6 years, overall survival in the 2
groups was virtually identical.
Comment: ELI may be useful in patients with a small
aortic root (<2.6 cm) and when the grading of severity is
inconsistent between AVA and mean gradient. In the latter
instance, it may be more prudent to proceed to careful and
complete cardiac catheterization and angiography by skilled
and experienced cardiologists.
3. Charlson comorbidity index. Two hundred thirty-
nine patients, age >60 years, from the Australian Depart-
ment of Veterans Affairs, were enrolled from 1988 to 1994
and followed until 2008 (14). During the follow-up, 132
patients developed severe AS (AVA <1.0 cm2 or mean
AVG >40 mm Hg). At 10 years, the survival of those
with severe AS with conservative management versus AVR
was 5  3% versus 50  5% (p < 0.001). The indepen-
dent predictors of all-cause mortality included age-adjusted
Charlson comorbidity index (HR: 1.24, 95% CI: 1.15 to
1.34, p < 0.001); left ventricular (LV) dysfunction (HR:
1.36, 95% CI: 1.09 to 1.71), p < 0.01; AVR (HR: 0.40,
95% CI: 0.28 to 0.58), p < 0.001.
Comment: The Charlson comorbidity index needs to be
an additive feature to the EuroSCORE or Society of
Thoracic Surgeons (STS) score in evaluating outcome in
AS, and therefore, also in clinical decision making for AVR.
4. Prognostic value of myocardial ﬁbrosis. Myocardial
ﬁbrosis was evaluated from biopsy specimens obtained from
the interventricular septum at the time of AVR in 99
patients (15). The relative volume of myocardial muscle and
ﬁbrous tissue was determined by point counting using a
10  10 grid at a total magniﬁcation of 100. The ﬁbrosis
index (FI) was calculated by dividing the sum of the ﬁbrotic
areas by that of the total tissue area, expressed as a per-
centage: no or mild ﬁbrosis (FI <20%; group 1), moderate
ﬁbrosis (FI 20% to 50%; group 2), or severe ﬁbrosis (FI
>50%; group 3). The ﬁbrous tissue mass index (FTMI) was
estimated as FI  LV mass index/100 (g/m2). There was a
positive correlation between FTMI and LV size and func-
tional class, and a negative correlation with LVEF. Hospital
mortality was 3%. Patients were followed for 6.2  2 years;
those in group 3 had the lowest survival (Fig. 2). The ﬁbrosis
and structural alterations occurred predominantly in the
Figure 2 Actuarial Freedom From Cardiac Death at 10 Years
Actuarial freedom from cardiac death at 10 years according to myocardial ﬁbrosis
grade 1 (ﬁbrosis index [FI] <20%) (orange), grade 2 (FI ¼ 20% to 50%) (green), or
severe (FI >50%) (blue). Reprinted with permission from Milano et al. (15).
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1950subendocardial layers and was followed by progression to all
layers of the myocardium. Patients with “signiﬁcant coronary
artery disease” were excluded.
Comment: The initial location of the ﬁbrosis is in the
subendocardium, and the subsequent progression suggests
ﬁbrosis may be related to myocardial ischemia as the result of
associated CAD and/or LV hypertrophy. Also, as discussed
later in the text, see the results of surgical aortic valve
replacement (S:AVR) and probably may affect results of
transcatheter valve treatment. There is a need for uniform
measurement and quantiﬁcation of the amount of ﬁbrosis
from gadolinium-enhanced images of magnetic resonance
imaging (MRI).
D. Management of AS. 1. Aortic balloon valvuloplasty
(ABV): poor results. Nine hundred patients were evaluated
from April 2007 to May 2011; 595 (66.1%) were assigned to
the medical/ABV group, of whom 354 had ABV and 241
had only medical therapy (16). In the medical/ABV group,
the 30-day mortality was 10.1%; 3- and 12-month mortality
was 20% and 45%, respectively, as evaluated from their
ﬁgure. In the medical/ABV group, the causes of death were
cardiac, noncardiac, and unknown in 38.9%, 28.1%, and
32.8%, respectively.
Comment: The data on outcomes in the medical/ABV
subgroup are similar to 7 previously published studies of
outcomes with ABV (17–23): 4 studies comprising 1, 480
patients showed the hospital/30-day mortality was 9.9%
(17–19,23); 1 study showed 6-month mortality was 50%
(22); 4 studies showed 1-year mortality ranged from 25% to
45% (17,18,20,21); 3 studies showed the 2-year mortality
was 40% to 65% (18,20,21); and 2 studies showed 2-year
event-free survival was 19% and 25% (18,21).
2. S:AVR: excellent results. From October 1991 to July
2010, 3,923 patients had AVR for AS: 1,637 (42%) had
AVR alone, 2,286 (58%) patients had AVR þ coronary
artery bypass grafting (CABG) (24). Their ages were 75 8.1 years versus 70  11 years, respectively. In the AVR þ
CABG group versus the AVR-alone group, hospital
mortality was 2.4% versus 1.3%, and survival at 1, 5, and
10 years was 91% versus 94%, 83% versus 90%, and 43%
versus 59%, respectively. There are a large amount of data
that are comprehensive, and the authors presented survival
in the overall group and in the propensity-matched pa-
tients. Ten-year survival in propensity-matched patients
showed the 10-year survival of isolated AS and AS þ
CAD was similar at 55% and 50%, respectively. Within
the isolated AS group, matched patients had a lower sur-
vival than unmatched patients with few comorbidities: 55%
versus 70%; AS þ CAD–matched patients had a better
survival than unmatched patients with myocardial damage
and many comorbidities: 50% versus 36% (Fig. 3). The
authors also concluded: “Patients with severe AS and CAD
risk factors should undergo early diagnostics and should
have AVR þ CABG before ischemic myocardial damage
occurs.”
Comment: The question is how early is early enough? In
this or similar age groups, the incidence of associated CAD
is up to 60% (25); in this study, it was 58%. I have suggested
that in the asymptomatic patient with severe AS, diagnostic
coronary contrast angiography followed by AVR may be very
valuable in managing patients in this age group (25) if: 1)
The operative mortality for subsequent AVR alone at an
institution is 1% to 2% and for AVR þ CABG is 2% to
4%. In the present study, it was 1.3% and 2.4%, respectively;
2) The stented bioprosthesis that is inserted has a docu-
mented low rate of structural valve deterioration (SVD) out
to 20 years (please also see the data on the Charlson co-
morbidity index [14] and on myocardial ﬁbrosis in the
preceding text [15]; and 3) It would be important and
clinically valuable if the study had described the outcomes up
to 10 years of the 741 patients who were asymptomatic at
baseline and also that of patients who had received 19-mm
prosthetic heart valves.
3. Low rate of complications of noncardiac surgery
(NCS) in patients with severe AS. In this study, 244
patients with severe AS undergoing NCS were matched to
976 who had no AS (26). Severe AS was deﬁned as
AVA <1.0 cm2, and patients had a variety of NCS. Out-
comes were evaluated at 30 days after NCS for mortality,
post-operative myocardial infarction (MI), heart failure, and
stroke compared with those with no AS. In the asymptomatic
AS group (n ¼ 172), the difference in each of the compli-
cations was not signiﬁcantly different compared with the
no-AS group. In the symptomatic severe AS group (n ¼ 72),
the incidence of post-operative MI was 5.6% versus 1.4% in
the no-AS group, p ¼ 0.009, but the incidence of the other
complications was not signiﬁcant; however, the incidence of a
combination of 30-day mortality and post-operative MI was
higher: 8.3% versus 2.7%, p ¼ 0.007. The authors stated,
“The heightened anesthetic management in patients with
severe AS is extremely relevant to current surgical practice
and represents the norm rather than the exception.”
Figure 3 Survival Of Propensity-Matched and Unmatched Patients
Survival of patients with isolated AS with few comorbidities (top blue curve). This is compared with matched isolated AS and few (non-CAD) comorbidities (middle blue curve) and
matched AS þ CAD (middle red curve). These are all contrasted with patients having AS and CAD with myocardial damage and many comorbidities (lower red curve). Vertical
bars represent conﬁdence limits equivalent to 1 standard error. AS ¼ aortic stenosis; CAD ¼ coronary artery disease. Reprinted with permission from Beach et al. (24).
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1951Comment: Previously, 3 studies with a combined total of
97 patients had similar ﬁndings (27–29). The National
Hospital Discharge Survey from 1996 to 2002 showed that
5,149 patients with a diagnosis of AS had undergone NCS
and were matched with 10,284 controls (30). There was no
signiﬁcantly increased risk of death in AS versus controls,
and the risk of perioperative MI was 3.86% versus 2.03%,
p < 0.001, with an OR of 1.55, 95% CI: 1.27 to 1.90,
p < 0.001 (30). Several of the studies emphasized careful
monitoring during anesthesia induction and the procedure,
and prevention of hypotension. Consideration should be
given to monitoring during NCS with the use of right-heart
balloon catheter and intra-arterial pressure.
E. Combined AS and aortic regurgitation is associated
with a higher event rate. Seventy consecutive asymptom-
atic patients (21 women, age 52  17 years, normal
LVEF 0.55) had “at least moderate AS” and “at least
moderate [aortic regurgitation (AR)]” (31). At a median
follow-up of 8.9 years, 50 patients developed an indication
for AVR, 43 had AVR, and 33 of the 43 developed symp-
toms. Event-free survival for the entire patient population at
1, 2, 3, 4, and 6 years was 82  5%, 62  6%, 49  6%, 33
 6%, and 19  5%, respectively. There were no cardiac
deaths.
Comment: The high event rate supports close follow-up
of these patients.
F. Discrete subaortic stenosis in adults. 1. Natural history:
slow progression. Data are from 149 patients at 4 centers
(32). Longitudinal follow-up data were available for 149 pa-
tients, age 20 years (interquartile range [IQR]: 18 to 34 years),
48% male Forty percent had associated congenital heartdefects; the baseline LV outﬂow tract (LVOT) gradient
was 32.3  17 mm Hg, which increased by 0.8  0.1 mm
Hg/year. Presence of a congenital heart defect was associated
with faster progression (p ¼ 0.005), mild AR was common,
but did not signiﬁcantly progress over time (p ¼ 0.701). The
median intervention-free survival was 16 years; the mean
age at discrete subaortic stenosis (DSS) surgery was 35.1
 14 years. Independent predictors for intervention were
LVOT gradient 50 mm Hg, LVOT gradient progression,
and moderate-to-severe AR.
2. High incidence of reoperation. Data are from 313
patients at 4 centers (33). The patients’ age was 20.2 years
(IQR: 18.4 to 31.0 years), 52% were male, and median
follow-up was 12.9 years (IQR: 6.2 to 20.1 years). There
was 1 operative death from heart failure. There were 10
late deaths; 20-year survival was 97%. Eighty patients
(25.6%) underwent at least 1 reoperation for recurrent
DSS, and 19 required a third operation (1.76% per pa-
tient year). Mean time from initial operation to reopera-
tion was 12.0  7.6 years. Predictors for reoperation
include female sex (HR: 1.53, 95% CI: 1.02 to 2.30) and
progression of LVOT obstruction (HR: 1.45, 95% CI:
1.31 to 1.62). Additional myectomy did not reduce the
risk for reoperation, but increased the risk of complete
heart block requiring pacemaker implantation (8.1% vs.
1.7%, p ¼ 0.005).
G. Heyde’s syndrome. 1. Beneﬁcial effects in Heyde’s
syndrome after AVR for severe AS. Bleeding in Heyde’s
syndrome is attributed to intestinal angiodysplasia. A
retrospective study identiﬁed 57 patients who underwent
AVR for severe AS who had intestinal angiodysplasia and
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1952gastrointestinal (GI) bleeding (34). The patients were age 74
 10 years, and AVA was 0.7  0.3 cm2. The number of
documented episodes of GI bleeding was 4  6 (range 1 to
27), the mean number of bleeds per patient-year was 12.
Melena, the most common symptom/sign, was present in
53%. Intestinal angiodysplasia was located in the right colon
in 28%, jejunum 25%, and right colon, plus another GI tract
location in 21%. CABG was also performed in 32%. There
were 2 operative deaths, none since 1987. The 1- and 5-year
survival were 93% and 59%, respectively. At follow-up of 4.4
years (range 0.1 to 15 years), 45 patients (79%) had no
further bleeding. In 12 (21%) patients, the bleeding episodes
were reduced from 4.7  7 to 1.9  2 patients per year.
Comment: From Heyde’s initial clinical observation in
1958 to 2012, studies have described the syndrome’s
fundamental biological mechanism (35). Of 3.8 million
patients discharged from public hospitals in Ireland, the
incidence of GI bleeding in patients with AS was 0.9% (36).
Bicuspid Aortic Valve
A. Cardiac MRI is better than 2-dimensional trans-
thoracic echocardiography for diagnosis of bicuspid aortic
valve. Of 1,203 patients who had an aortic valve operation,
218 had both pre-operative 2-dimensional transthoracic
echocardiography (2D TTE) and cardiac MRI (cMRI);
bicuspid aortic valve (BAV) was conﬁrmed in 123 patients
(37). Of these 123 patients, 2D TTE conﬁrmed BAV in 76
(62%), misidentiﬁed 12 (10%) as tricuspid valve, and was
nondiagnostic in 35 (28%). In the same 123 patients, cMRI
conﬁrmed BAV in 115 (93%), misidentiﬁed 5 (4%) as
tricuspid valve, and was nondiagnostic in 3 (2%). The dif-
ference in identifying BAV by 2D TTE versus cMRI was
signiﬁcant (p < 0.001). In the entire cohort of 218 patients,
2D TTE was diagnostic for valve morphology in 155 (71%),
and cMRI was diagnostic in 212 (97%), p < 0.001.Figure 4 20-Year Outcomes After CBC
Shown are catheter balloon commissurotomy (CBC) without further surgery (left) and goo
surgical mitral commissurotomy (CBC). Reprinted with permission from Bouleti et al. (38Mitral Stenosis
Excellent 20-year results of catheter balloon commis-
surotomy for restenosis after previous surgical mitral
commissurotomy. One hundred sixty-three patients had
catheter balloon commissurotomy (CBC) (called percuta-
neous mitral commissurotomy) as a result of bicommissural
fusion for restenosis after surgical commissurotomy (38).
Good immediate result (valve area 1.5 cm2 and mitral
regurgitation [MR] 2/4) was obtained in 135 (83%). In
those with a good immediate result, the 20-year results were
mortality of 17%, repeat CBC in 18%, survival without sur-
gery was 33.2  5.5%, and good functional result (cardio-
vascular survival and New York Heart Association [NYHA]
functional class [FC] I/II) was 17.9  4.7% (Fig. 4).
B. Progressively increasing signiﬁcant tricuspid regurgi-
tation on long-term follow-up after successful CBC for
severe MS. A prospective study of 299 patients showed
that after successful CBC, tricuspid regurgitation (TR)
regressed (39). However, 56 patients developed signiﬁcant
TR (grade 3 on echocardiography/Doppler) during
follow-up (median 12 years, IQR: 8.0 to 18 years). The
increase was time dependent; at 8, 12, and 18 years after
CBC, signiﬁcant TR was present in 9.4%, 19.8%, and
35.2%, respectively. Atrial ﬁbrillation (A Fib), TR grade 2
before CBC, and mitral valve restenosis were important
factors for de novo development of late TR.Mitral Regurgitation
A. Resuscitant from sudden death: triad of bileaﬂet
mitral valve prolapse in women, ST–T-wave changes on
electrocardiogram, and frequent complex ventricular
ectopic activity. Twenty-four of 1,200 patients in the
Mayo Clinic Long QT Syndrome/Genetic Heart Rhythm
Clinic had idiopathic out-of-hospital cardiac arrest (i.e.,d functional results (right). Data are after CBC for recurrent mitral stenosis after
).
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1953negative for ischemia, cardiomyopathy, and channelopathy)
(40). All had implantable cardioverter-deﬁbrillators (ICDs).
Out-of-hospital cardiac arrest had occurred in 22 (92%).
Ten of 24 (42%) had bileaﬂet mitral valve prolapse (MVP),
and comparing these patients to those with normal mitral
valves, the incidence in women was 90% versus 50% (p ¼
0.04), and had a higher incidence of biphasic or inverted
waves 77.8% versus 29% (p ¼ 0.04). On Holter monitoring,
they had a higher prevalence of: 1) ventricular bigeminy:
100% versus 10%, (p < 0.0001); 2) ventricular tachycardia:
78% versus 10% (p ¼ 0.006); and 3) premature ventricular
contractions originating from the outﬂow tract alternating
with the papillary muscle or fascicular region: 78% versus
28%, (p ¼ 0.02) (Fig. 5). Over a median follow-up of 1.8
years (range 0.1 to 11.9 years) after ICD placement, 13 of 24
(54%) patients received appropriate ICD shocks for ven-
tricular ﬁbrillation. Only bileaﬂet MVP was associated with
ventricular ﬁbrillation requiring ICD therapy (p ¼ 0.028).
Comment: Very important data. It should be emphasized
that no patient of the 24 idiopathic out-of-hospital cardiac
arrests had prolapse of only 1 leaﬂet.
B. Longitudinal outcomes of mitral valve repair in
patients ‡65 years of age. Data are presented from the
STS database in 14,604 patients who had mitral valve repair
(MVrep) from 1991 to 2007 (41). Patients were age 73.3 
5.5 years, LVEF was 0.54  0.13, 55.8% were female, and
8.4% were non-Caucasians. Operative mortality was 2.59%,
and follow-up was 5.9  3.9 years (range 1 to 18 years). The
10-year actuarial survival was 57.4%. The 10-year actuarial
rates of mitral reoperation, heart failure, bleeding, and stroke
were 6.2%, 30.1%, 15.3%, and 16.4%, respectively.
Comment: Interesting data. Those data that were
important and clinically valuable, but were not presented,
included: 1) the number of patients who had mitral valve
replacement (MVR) during the same time period; 2) the
conﬁdence intervals of survival and of events; 3) the inci-
dence and severity of recurrent MR, which is likely to be
underestimated by evaluating the reoperation rate; and 4) the
mortality and incidence of heart failure were “high.”
Therefore, there is a need to document the extent and in-
tensity of medical treatment on follow-up and at baseline,
the incidence of associated CAD based on ﬁndings from
coronary arteriography, risk factors for CAD, the incidence
of moderate and severe MR, the frequency and severity of
renal dysfunction, and the causes of death (please also see
late outcomes of MVrep in the following text).
C. MVP with a near 100% MVrep rate. From 2002 to
2010, MVrep was performed by a single surgeon in 744
consecutive patients; 1 patient had to be converted to MVR
(42). Patients were age 58  13 years (range 12 to 90 years),
21% were 70 years of age, LVEF was 0.55  0.09, 12%
were in NYHA FC III/IV, and MR was moderately severe
in 6.5% and severe in 93.5%. Thirty-day mortality was
0.9%. One- and 5-year survival was 99.2  0.3% and 97.4
 0.8%, respectively. Seventy percent had late follow-upechocardiography at a follow-up time of 1.5  1.1 years
(range 7 to 2,527 days) that showed recurrent 2þ MR at
7 years of 9%.
D. Late (20-year) outcomes of MVrep. From 1985 to
2004, all 840 patients who had MVrep for “degenerative”
MR were reported (43). Their median age was 60 years
(IQR: 50 to 68 years), and NYHA FC was I, II, III, and IV
in 15.1%, 36.7%, 36.8%, and 11.3%, respectively. LVEF
0.60 occurred in 60.1%, severe MR in 95%, and moderate
MR in 5%. STS risk score was 1.5% (95% CI: 0.3% to 5.5%).
Thirty-day mortality was 4 of 840 (<0.5%). Follow-up times
ranged from 0 to 26 years, median was 10.4 years (IQR:
7.4 to 13.7 years). Clinical follow-up was complete in 98.4%
of patients. Echocardiographic follow-up extended from
0 to 26 years (median 10.3 years, IQR: 7.5 to 13.3 years) and
was complete in 94.9%. By echocardiography/Doppler,
valve function was evaluated and data were presented at
5 to 10 years, 10 to 15 years, 15 to 20 years, and >20 years
in 97%, 94%, 90%, and 76% of patients, respectively. Out-
comes at 10 and 20 years are shown in Table 1.
Comment: Very impressive follow-up data that are
comprehensive. Excellent outcomes. Note: The low STS
risk score and 52% of patients were in NYHA FC I and II.
E. Late outcomes after double-oriﬁce MVrep combined
with ring annuloplasty. The edge-to-edge (E-to-E) pro-
cedure produces a double-oriﬁce mitral valve. From 1993 to
2000, 174 patients with severe degenerative MR had E-to-E
plus ring annuloplasty (44). They comprised 24.5% of patients
who hadMVrep during this time period. They were age 52
18 years, 71% of patients were in NYHA FC I/II, and A ﬁb
was present in 17.2%. Follow-up was 11.5 2.53 years (range
1.1 to 17.6 years) and was complete in 169 (97.1%), 55 pa-
tients had an echocardiogram at the authors’ institution, and
114 patients within the previous 6 months by the referring
local cardiologist. MR was due to anterior, posterior, and
bileaﬂet prolapse in 20.6%, 5.7%, and 73.5%, respectively.
There were no hospital deaths, actuarial survival at 14 years
was 86.9 3.37, and freedom from cardiac death was 95.8
1.54%. Freedom of reoperation was 89.6  2.51%. Mitral
stenosis requiring reoperation was detected in 1 patient
(0.6%). Mitral valve area was 3.2  0.4 cm2, and MR was
absent in 24.8%, mild in 49.1%, moderate in 12.4%, and
moderate to severe in 3.5%. Recurrence ofMR3þ occurred
at a median of 8.2 years (IQR: 2.8 to 10.7 years); the only
predictor of recurrence of MR 3þ was residual MR greater
than mild at hospital discharge. The incidence of NYHA
FC I, II, and III was 66.2%, 28.9%, and 4.7%, respectively
(p ¼ 0.0001 compared with pre-operative values).
Infective Endocarditis
A. Persistent positive blood cultures at 48 to 72 h
after initiation of antibiotic treatment for left-sided
infective endocarditis is associated with increased
in-hospital mortality. Of 256 patients with positive
blood cultures, 89 (35%) had persistent positive blood
Figure 5 Malignant Bileaﬂet MVP in Patients With Previous Cardiac Arrest
A phenotype of life-threatening ventricular arrhythmias with: 1) bileaﬂet mitral valve thickening and mitral valve prolapse (MVP) in women (systolic [top] and diastolic [bottom]
parasternal long-axis views of the heart are shown) (A); 2) T-wave changes in the inferior leads (B); and 3) frequent ventricular ectopic activity with premature ventricular beats of
outﬂow tract origin alternating with papillary muscle or fascicular origin (C). Reprinted with permission from Sriram et al. (40).
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1954cultures at 24 to 72 hours, which was associated with
a doubling of in-hospital mortality (OR: 2.1, 95%
CI: 1.2 to 3.6) (45). Other independent predictors
of in-hospital mortality were staphylococcal infection
(OR: 3.3), renal failure (OR: 2.9), heart failure (OR: 2.8),
and age (OR: 1.026).
Comment: Forty-three percent of the 99 patients with
prosthetic valve endocarditis had positive blood cultures at
48 to 72 h compared with 29% of patients with native valve
endocarditis. About 90% of patients with Streptococcus vir-
idans infection had negative blood cultures at 48 to 72 h.
B. Neurological complications of infective endocarditis:
most embolic events occur during the ﬁrst 7 days of
antibiotic therapy. Data are from a prospective multicenter
study from 8 centers in Spain from 1984 to 2009. Of 1,345
consecutive episodes of left-sided infective endocarditis, 340(25.3%) had 1 neurological complication (46). Ischemic
events were the most frequent of these complications and
occurred in 192 of 340 (56%) patients. Overall mortality was
30%; neurological complications accounted for 45% of the
deaths. Antibiotic therapy reduced the neurological compli-
cations by 33% to 75%. Importantly, 163 of 192 (85%)
ischemic events while on antibiotic therapy occurred in 133
of 163 (82%) patients. Of these, ischemic events occurred
7 days of starting antibiotic therapy. Surgery was performed
in only 523 of 710 (39%) of those in whom it was indicated.
C. The addition of 18F-FDG positron emission tomo-
graphy/computed tomography toechocardiography improves
the diagnosis of prosthetic heart valve endocarditis. Seventy-
two patients suspected of prosthetic heart valve (PHV) endo-
carditis (PVE) were prospectively studied (47), 36 (50%) of
whom exhibited abnormal FDG uptake around the site of the
Table 2
Distribution of Debris Found in the
Overall Patient Cohort
Histopathologic Characteristics
Cases, n
(N ¼ 30)
1 Calcium þ valve tissue þ thrombus 3
2 Calcium þ valve tissue 2
3 Valve tissue 3
4 Thrombus 8
5 Thrombus þ necrotic core 1
6 Thrombus þ collagenous tissue 9
7 Collagenous tissue 4
Values are derived from parametric survival regression models. Reprinted with permission from
Van Mieghem et al. (49).
Table 1
Survival Estimates and Freedom From Adverse
Events at Various Time Intervals From Competing
Risk Models and From Parametric Survival
Regression Models
Outcomes
10 Years 20 Years
(95% CI) (95% CI)
Competing risk, 100%*
Valve-related death 3.7 (2.6–5.1) 11.3 (8.0–15.7)
Cardiac death (nonvalve) 2.8 (1.9–4.2) 7.8 (5.2–11.7)
Noncardiac death 7.4 (5.9–9.3) 23.7 (18.9–29.2)
Reoperationy 4.1 (3.0–5.6) 5.9 (4.3–8.0)
Alive and reoperation-freey 82.1 (76.5–86.5) 51.9 (43.0–60.6)
Freedom from other outcomes
All-cause mortality 85.8 (84.5–86.9) 54.8 (51.8–57.8)
Mitral reoperation 95.9 (94.4–97.0) 94.1 (92.0–95.7)
Mitral regurgitation
Severe 95.5 (94.8–96.2) 90.7 (88.9–92.2)
Moderate/severe 90.4 (89.3–91.4) 69.2 (65.8–72.5)
Endocarditis 99.0 (98.5–99.3) 98.5 (97.8–99.0)
Thromboembolism 90.8 (89.7–91.7) 85.7 (84.1–87.3)
*These are proportion of patients, freedom ¼ 100  (proportion of patients). yReoperation on the
mitral valve. Adapted with permission from David et al. (43).
CI ¼ conﬁdence interval.
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1955PHV. The sensitivity, speciﬁcity, positive predictive value,
negative predictive value, and global accuracy of FDG uptake
were 73%, 80%, 85%, 67%, and 76%, respectively. Adding
abnormal FDG uptake around the PHV increased the sensi-
tivity of the modiﬁed Duke criteria at admission from 70% to
97%, p ¼ 0.0008; the result was due to a signiﬁcant reduction
(p < 0.0001) in the number of possible PVE cases from 40
(56%) to 23 (32%).
Comment: The accurate diagnosis of PVE is clinically
very important but can be problematic. Cardiac positron
emission tomography/computed tomography could become
a very useful additional diagnostic test.
Transcatheter Valve Therapy
Aortic
A. Updated standardized endpoint deﬁnitions for trans-
catheter aortic valve implantation (48).
B. Histopathology of embolic debris captured during
aortic transcatheter valve therapy. Forty patients under-
went aortic transcatheter valve therapy (TVT) with use of a
dual-ﬁlter–based embolic protection device (Montage Dual
Filter System, Claret Medical, Santa Rosa, California) (49).
The debris had 7 different histopathologic characteristics
(Table 2). There were different types of thrombus (Fig. 6).
Comment: An important study.
C. TVT for SVD of bioprosthetic PHV: data from the
Global Valve-in-Valve Registry. Data are from 202
patients in 38 cardiac centers, age 77.7  10.4 years, 52.5%
male. They had received a CoreValve (n ¼ 124) (Medtronic,
Minneapolis, Minnesota) or Edwards Sapien valve (n ¼ 78)
(Edwards Lifesciences, Irvine, California) for TVT (50). The
mode of failure of the bioprosthesis was stenosis in 42%,regurgitation in 34%, and stenosis plus regurgitation in 24%.
Procedural success rate was 93.1%; adverse outcomes included
device malposition in 15.3% and ostial coronary obstruction
in 3.5%. Stroke rate was 2%, AR grade 2þ occurred in 5%,
and the mean AVG was 15.9  8.6 mm Hg. Thirty-day and
1-year mortality rates were 8.4% and 14.2%, respectively.
Pre-procedure, 94.2% were in NYHA FC III/IV. At 1 year,
49% and 35.1% were in NYHA FC I and II, respectively.
Comment: An important direction of TVT with
impressive early results. A review documented outcomes of
this procedure in detail (51). It is still a very early stage of
this procedure; inappropriate conclusions that may result in
changes in clinical practice should be avoided.
D. Women have better short- and long-term survival
with TVT. Consecutive 641 patients undergoing aortic
TVT in 2 centers in Canada were evaluated (52); 329 (51.3%)
were women, and 312 were men. Balloon-expandable valves
were used in 97% with a transapical approach in 51.7% in
men and 38.1 % of women. Porcelain aorta was present
in 29.2% of the women and 12.0% of the men, p < 0.001.
Women had more major vascular complications (12.4% versus
5.4%, p ¼ 0.0003) and needed more blood transfusions (9.5%
versus 3.6%, p ¼ 0.005), but had a lower 30-day mortality.
The survival in women versus men was 82.7% versus 72.5%
at 1 year, and 72.1% versus 61.7% at 2 years, p ¼ 0.007.
Mitral
A. Immediate effects of reduction of MR by mitral clip
on LV remodeling and loading conditions. Thirty-three
patients, age 78  10 years, with functional (45%), degen-
erative (48%), or mixed (6%) MR (53), were studied acutely
while still under anesthesia immediately before and after
placement of the MitraClip (Abbott Vascular, Santa
Clara, California). Standard right-heart catheterization and
LV catheterization using a conduction catheter were per-
formed, which allowed obtaining continuous measurements
of the LV pressure and volume, and allowed measurement/
calculation of LV afterload, pre-load, end-diastolic and
end-systolic stress, contractility, myocardial energetics, and
hemodynamics. The authors summarized their ﬁndings as:
“1) Reduction of MR by TVT results in an acute increase of
LV afterload and reduction of preload. A signiﬁcant increase
Figure 6 Type of Thrombus in Embolic Debris With TVT
(A) Platelet-rich acute thrombus with focal presence of neutrophils. (B) High-power magniﬁcation of the boxed area in A. (C) Organizing chronic thrombus. (D) High-power
magniﬁcation of the boxed area in C with the presence of spindle-shaped cells and focal sparse macrophages with occasional capillaries (arrows). (E and F) High-power images
of an organizing thrombus with interspersed ﬁbrin and proteoglycans (green in the Movat-stained tissue in F). (A to E) hematoxylin and eosinophil–stained sections; (F) a Movat
pentachrome–stained section. TVT ¼ transcatheter aortic therapy for aortic stenosis. Reprinted with permission from Van Mieghem et al. (49).
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1956in forward cardiac output and decrease of pulmonary pres-
sures indicates the increase in afterload is outweighed by
end-diastolic unloading; 2) Despite a decline in LVEF,
LV contractility is not signiﬁcantly affected; 3) LV total
mechanical energy remains unchanged and therefore myo-
cardial oxygen consumption is not expected to increase; and
4) The beneﬁcial hemodynamic changes with preserved
LV contractility reverses LV remodeling by reducing end-
diastolic volume. At 3 months, NYHA functional class
and LV dilatation were improved.”
Comment: Sophisticated and excellent study.Prosthetic Heart Valve
A. STS clinical practice guidelines: executive summary.
Comment: These guidelines (54) present the viewpoint of
the STS with regard to the surgical aspects of heart valves
and of the ascending aorta, and include recommendations of
the surgical aspects of aortic root, ascending aortic dissec-
tion, ascending aorta, and aortic arch.
The STS guidelines have 83 Class I recommendations,
of which 6 (7.2%) are based on Level of Evidence: A.
Moreover, 2 of the recent randomized trials that have
been cited have signiﬁcant problems (55,56). Of the 145
recommendations, the Level of Evidence was C in 62%.
B. Anticoagulation of older patients receiving AVR with
bioprosthetic valves: is aspirin alone adequate? Data are
from 25,656 patients age 65 years in the 2004 to 2006STS database (57), their median age was 77 years (IQR: 72
to 81 years), 39.4% were women. A total of 13,458 (52.5%)
patients had a prior history of 1 risk factor for early
thromboembolism at hospital discharge: A ﬁb in 41.1%,
thromboembolism in13.6%, or LVEF <0.30 in 4.8%. At
hospital discharge, 12,457 (48.6%) received aspirin only
(group A), 2,999 (11.7%) received warfarin only (group B),
and 5,972 (23.3%) received aspirin plus warfarin (group C).
The 3-month incidence of death in these 3 groups was 3.0%,
4.0%, and 3.1%, respectively, and of bleeding was 1.0%,
1.4%, and 2.8%, respectively.
Comment: The answer is yes unless there is an associated
comorbid condition for which there is a widely accepted
indication for warfarin therapy. There is a very recent ran-
domized trial indicating beneﬁt regarding improved graft
patency with use of aspirin þ clopidogrel in patients un-
dergoing off-pump CABG (58,59). Should we apply this
ﬁnding to patients undergoing AVR þ CABG? I believe the
answer is also yes at the present time.
C. Previous CABG does not increase mortality or
morbidity of reoperative valve surgery. A total of 1,093
consecutive patients underwent reoperative cardiac surgery
between 2000 and 2010 (60), of whom 363 had isolated
reoperative valve surgery. Their age was 62  16 years;
38.8% were female; the time from previous surgery was
8.6  7.8 years, and 15% of reoperative surgery occurred
within 1 year of the initial operation. In group A patients
(n ¼ 133), the previous surgery had included CABG; in
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1957group B (n ¼ 230), patients had not had previous CABG.
In group A patients, 94% had patent grafts. Operative
mortality was 4.1%. In propensity-matched patients, there
was no statistically signiﬁcant difference between the 2
groups for mortality or morbidity. Group A patients had a
lower 5-year survival rate than group B patients, but in
propensity-matched patients, the difference was not statis-
tically signiﬁcant. Multivariate predictors of decreased sur-
vival were severe pulmonary hypertension (OR: 2.76),
diabetes mellitus (OR: 2.01), NYHA FC III or IV (OR
1.69), logistic EuroSCORE (OR: 1.04), and peripheral
vascular disease (OR: 0.55).
D. Outcomes of David valve-sparing aortic root
replacement is similar in those with bi- and tricuspid
aortic valves. Two hundred thirty-three patients (BAV in
27%, Marfan syndrome in 40%) underwent Tirone David’s
valve-sparing aortic root replacement from 1993 to 2009
(61). Survival at 5 and 10 years was 98.7  0.7% and 93.5
 5.1%. At 5 and 10 years, there was no statistically sig-
niﬁcant difference between patients with bi- and tricuspid
aortic valves in survival, reoperation, SVD, or any other
functional or clinical endpoints, including those with asso-
ciated connective tissue disorder.
E. Long-term survival after S:AVR among the high-risk
“elderly” from the STS database 1991 to 2007. Data on
103,500 Medicare-linked S:AVR patients from 1999 to
2007 are presented (62). Patients were categorized by pro-
cedure type (AVR, AVR þ CABG) and age (65 to 69,
70 to 79, and 80 years). Operative mortality of AVR
(n ¼ 43,809) and of AVR þ CABG (n ¼ 59,691) were
3.9% and 5.0%, respectively. For patients in the 65 to 69,
70 to 79, and 80 years of age groups, the median survival
after AVR was 12.8, 9.2, and 6.2 years, respectively, and for
AVR þ CABG was 10.4, 8.2, and 5.9 years, respectively.
Median survival was also presented by categorization to
several high-risk groups. Severe lung disease and renal failure
were each associated with a 50% reduction in median
survival among all age groups. The survival is said to be
“excellent” and was matching that of a “similarly aged U.S.
population.”
Comment: These data are important. However, data
that are clinically valuable, but not presented, included:
1) operative mortality in the 3 subgroups characterized by
age: 2) IQR of the median survival; 3) survival curves do
not present, either in the text or ﬁgures, the CIs and
numbers of patients at risk; and 4) data that match the
survival to that of the U.S. population. Note also that 1
criterion of renal failure in the STS database (creatinine
>2.0 mg/l) does not precisely delineate the extent of renal
dysfunction.
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